Omura G A
Cancer Clin Trials. 1981;4(2):219-20.
A recent chemotherapy trial in ovarian carcinoma raised questions about the diagnosis and staging of this disease. Review of the protocol records indicated that all 45 patients had a histologic or cytologic diagnosis of carcinoma. However, in three cases it was not stated how the primary site was determined. Another four cases were not explored, while eight others were explored, but the primary was not identified; the pathologic material was "consistent" with ovarian adenocarcinoma. Thus, one-third (15) of the patients had not had their primary adequately demonstrated. Published studies of advanced ovarian cancer typically refer to the FIGO staging system and imply that the primary lesion was actually identified, but review of the operative report and slide review of the primary lesion are not always described or required. Casually diagnosed cases should be labeled as such and evaluated separately.
最近一项针对卵巢癌的化疗试验引发了关于该疾病诊断和分期的问题。对方案记录的审查表明，所有45名患者均有癌的组织学或细胞学诊断。然而，有3例未说明如何确定原发部位。另有4例未进行探查，还有8例进行了探查，但未确定原发灶；病理材料与卵巢腺癌“相符”。因此，三分之一（15例）患者的原发灶未得到充分证实。已发表的关于晚期卵巢癌的研究通常参考国际妇产科联盟（FIGO）分期系统，并暗示实际已确定原发病变，但并不总是描述或要求审查手术报告和对原发病变的玻片检查。偶然诊断的病例应如此标记并单独评估。
